Cambridge and CRUK spinout Inivata has more than doubled its series C round to $60m following a $35m extension backed by IP Group.
Inivata, a UK-based precision cancer diagnostics spinout of University of Cambridge and Cancer Research UK, increased its series C round to $60m today following a $35m extension backed by commercialisation firm IP Group.
Soleus Capital has led the round, which also featured Janus Henderson Investors and Farallon Capital. Cancer diagnostics service provider NeoGenomics had provided the first $25m tranche as part of a strategic collaboration agreement in May 2020.
Founded in 2014, Inivata has created a highly…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
